Novartis Intrinsic Value
NOVARTIND Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹950.40 | ₹760.32 - ₹1140.48 | +18.8% | EPS: ₹43.20, Sector P/E: 22x |
| Book Value Method | asset | ₹1308.33 | ₹1177.50 - ₹1439.16 | +63.5% | Book Value/Share: ₹654.17, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹660.00 | ₹594.00 - ₹726.00 | -17.5% | Revenue/Share: ₹330.00, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1183.33 | ₹1065.00 - ₹1301.66 | +47.9% | EBITDA: ₹142.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹848.96 | ₹679.17 - ₹1018.75 | +6.1% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹240.01 | ₹216.01 - ₹264.01 | -70.0% | EPS Growth: 1.1%, Fair P/E: 0.8x |
| Growth Adjusted P/E | growth | ₹640.84 | ₹576.76 - ₹704.92 | -19.9% | Revenue Growth: -2.2%, Adj P/E: 14.8x |
| ROE Based Valuation | profitability | ₹1070.00 | ₹963.00 - ₹1177.00 | +33.7% | ROE: 13.6%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹797.40 | ₹717.66 - ₹877.14 | -0.3% | EPS: ₹43.20, BVPS: ₹654.17 |
Want to compare with current market value? Check NOVARTIND share price latest .
Valuation Comparison Chart
NOVARTIND Intrinsic Value Analysis
What is the intrinsic value of NOVARTIND?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Novartis (NOVARTIND) is ₹848.96 (median value). With the current market price of ₹800.05, this represents a +6.1% variance from our estimated fair value.
The valuation range spans from ₹240.01 to ₹1308.33, indicating ₹240.01 - ₹1308.33.
Is NOVARTIND undervalued or overvalued?
Based on our multi-method analysis, Novartis (NOVARTIND) appears to be trading near calculated value by approximately 6.1%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 35.52 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Debt to Equity Ratio | 1.21 | Industry Standard: <0.5 | Above 1.0 | Indicates financial leverage level |
| Return on Equity | 13.6% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 28.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.42x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
Related Pages for Novartis
Additional stock information and data for NOVARTIND
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹75 Cr | ₹74 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹113 Cr | ₹113 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹45 Cr | ₹-32 Cr | Positive Operating Cash Flow | 6/10 |
| March 2022 | ₹39 Cr | ₹39 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-69 Cr | ₹-69 Cr | Negative Cash Flow | 3/10 |